• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

Country Philippines

Article

Pharmaceutical Executive

Pharmaceutical ExecutivePharmaceutical Executive-02-01-2014
Volume 0
Issue 0

Connecting the Dots The inclusion of healthcare as a priority on the presidential agenda has led to knock-on consequences that are being felt across the healthcare value chain in the Philippines. Universal healthcare coverage (UHC) has been cemented, which has led to a shift from branded medicines to generics, leading many players to a strategic repositioning. The most successful players have been those who focused on a strategy that was inclusive of all stakeholders and aligned with the presidential agenda of affordable and accessible healthcare.

External Link - article-834930.doc

Articles in this issue
i12_t-834930-1408525551008.gif
Country Philippines
line-834478-1408526138664.gif
Will Europe's Regulatory Watchdog Come Of Age In 2014?
Managed Markets: Positioning Your Product For Success with Pull Through Strategies
Managed Markets: Positioning Your Product For Success with Pull Through Strategies
line-834481-1408526130758.gif
Russian Innovation: A Higher Mark
The Active Patient: Faces Of Change
The Active Patient: Faces Of Change
line-834480-1408526133448.gif
Social Media: Have We Reached The Tipping Point?
Takeda's Oncology Taskmaster
Takeda's Oncology Taskmaster
Product Positioning 2.0
Product Positioning 2.0
line-834479-1408526136002.gif
A Spark From GSK
Related Content
The Pharmaceutical Playbook for Asia’s Private Market

The Pharmaceutical Playbook for Asia’s Private Market

April 11th 2024
Article

Is it possible to win in Asia’s private market?

Bruce Liu

Fresh Formulas for Growth: Assessing Asia in the New Year

February 8th 2024
Article

The three key themes likely to shape pharma fortunes in 2024.

Adam Zhang

Out-licensing Deals Between Chinese Pharma and Global Companies are Heating Up

January 19th 2024
Article

A growing number of domestic drug developers are setting their sights on overseas markets.

Professor F. Warren McFarlan, DBA, MBA, AB

Should Biopharma C-Suites Still Engage With China? A Harvard Business School Healthcare Alumni Association Q&A with Professor F. Warren McFarlan

November 16th 2023
Article

An overview of what biopharma C-Suites and their boards should consider when engaging with government and business leaders from China, the world’s second largest economy.

Ramees Raja

Q&A With Ramees Raja, Global Energy Manager at Almac Group

November 3rd 2023
Article

Raja discusses how the pharma industry can improve its ecological impact.

Bruce Liu

The Rising Importance of Patient Advocacy Innovations in Asia

October 11th 2023
Article

Effective engagement—from research to reimbursement—is key.